PROFILE: Paula Salmikangas, chair of the EMA's Advanced Therapies Committee, on handicrafts, berry-picking and the first stem cell therapy
This article was originally published in Scrip
Executive Summary
The European Medicines Agency's Committee for Advanced Therapy Medicinal Products (CAT) evaluates the quality, safety and efficacy of ATMPs. Since February 2014, the CAT has been chaired by senior Finnish regulator Paula Salmikangas. Here, Dr Salmikangas talks to Francesca Bruce about the pitfalls of rushing a product from bench to patient, the value to companies of talking to regulators – and her passion for berry-picking and the Phantom of the Opera.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.